Pulse Biosciences, Inc. Releases Q1 2026 Financial Results and Business Update

Pulse Biosciences, Inc. (NASDAQ: PLSE) has announced its financial and operational results for the first quarter ended March 31, 2026. The company, a leading developer of proprietary Nano-Pulse Stimulation™ (NPS™) technology, provided key financial metrics and business updates that are critical for investors and shareholders.

Key Highlights from the Q1 2026 Report

• Revenue: Product revenue for Q1 2026 was reported at \$401,000.
• Net Loss: The company reported a GAAP net loss of \$18.6 million for the quarter, compared to a net loss of \$16.8 million in the prior year period.
• Loss from Operations: Loss from operations was \$19.2 million, an increase from \$18.0 million in Q1 2025.
• Research & Development (R&D) Expenses: R&D expenses stood at \$12.6 million, up from \$10.3 million in the same period last year, highlighting continued investment in product development and technology.
• Selling, General and Administrative (SG&A) Expenses: SG&A was \$6.6 million, down from \$7.7 million in Q1 2025.
• Cash and Cash Equivalents: As of March 31, 2026, the company had \$66.3 million in total stockholders’ equity, compared to \$80.7 million at December 31, 2025.
• Weighted Average Shares Outstanding: 68,225,067 shares as of March 31, 2026.
• Non-GAAP Measures: Non-GAAP net loss was \$16.4 million for the quarter.

Investor-Relevant and Potentially Price-Sensitive Information

• Widening Net Loss and Increased R&D Spending: Pulse Biosciences continues to incur significant losses, which increased year-over-year. The company’s ongoing commitment to R&D suggests a strong focus on future product innovation, but also indicates ongoing cash burn. This could weigh on share price unless offset by future revenue growth or breakthroughs in product development.
• Revenue Remains Modest: Despite proprietary technology and ongoing development, product revenue remains relatively low compared to operating expenses, suggesting that the company is still in the early stages of commercial adoption. Investors should closely monitor signs of revenue acceleration in future quarters.
• Stock-Based Compensation and Legal Settlement: Non-GAAP adjustments included \$1.9 million in stock-based compensation and a \$590,000 legal settlement in Q1 2026. Such items can impact short-term expenses and perceptions of underlying business performance.
• Forward-Looking Statements and Risks: The company emphasizes that its forward-looking statements are subject to risks and uncertainties. Actual results may differ materially from those anticipated due to factors detailed in the company’s SEC filings, particularly its most recent Annual Report on Form 10-K.
• Balance Sheet Considerations: Total assets decreased, and while equity remains positive, the trend of declining equity due to ongoing losses could become a concern if not offset by future revenue growth or capital raises.
• Investor Contact: The company encourages investors to contact Jon Skinner, CFO, at [email protected] for further inquiries.

Non-GAAP Financial Measures

Pulse Biosciences supplements its GAAP results with non-GAAP financial measures, adjusting for stock-based compensation, depreciation and amortization, and legal settlements. Management believes these non-GAAP measures offer a clearer picture of ongoing operations, but cautions investors about potential limitations and encourages reviewing the provided reconciliations.

Forward-Looking Statements

The release contains forward-looking statements regarding financial results, future operations, expenses, and anticipated cash flows. These statements are subject to significant risks, including but not limited to those described in the company’s SEC filings. The company undertakes no obligation to update such statements.

Conclusion

Shareholders should note: The continued increase in net loss and R&D spending, alongside relatively modest revenue, may influence share price volatility. While these results could pressure the stock in the short term, ongoing investment in NPS technology and a focus on product development could offer long-term upside if successful commercialization is achieved. Investors are advised to watch future earnings for signs of revenue growth or strategic partnerships that could materially improve the company’s financial trajectory.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own research and consult with financial professionals before making investment decisions. All forward-looking statements are subject to risks as stated by the company, and actual results may differ materially from projections.

View PULSE BIOSCIENCES, INC. Historical chart here